1. Andresen, K., Boberg, K.M., Vedeld, H.M., Honne, H., Hektoen, M., Wadsworth, C.A., Clausen, O.P., Karlsen, T.H., Foss, A., Mathisen, O., Schrumpf, E., Lothe, R.A. & Lind, G.E. (2012) Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics, 7, 1249-1257.
2. Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P., Irwig, L.M., Lijmer, J.G., Moher, D., Rennie, D. & de Vet, H.C.; Standards for Reporting of Diagnostic, Accuracy (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin. Chem., 49, 1-6.
3. Brait, M., Ling, S., Nagpal, J.K., Chang, X., Park, H.L., Lee, J., Okamura, J., Yamashita, K., Sidransky, D. & Kim, M.S. (2012) Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers. PLoS One, 7, e44951.
4. Bruix, J., Boix, L., Sala, M. & Llovet, J.M. (2004) Focus on hepatocellular carcinoma. Cancer Cell, 5, 215-219.
5. Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., Christensen, E., Pagliaro, L., Colombo, M. & Rodes, J.; EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol., 35, 421-430.